Why OncoMed (OMED) Shares Flew Sky High

NEW YORK (TheStreet) -- Shares of OncoMed Pharmaceuticals (OMED) opened sharply higher on news the small-cap biopharmaceutical company was partnering with biotech industry leader Celgene  (CELG). As part of the agreement, the two companies will develop and co-market up to six anti-cancer stem cell medicines in OncoMed's pipeline.

At Tuesday's open, OncoMed shares were up 77.4% to $23.99.

OncoMed will be responsible for early clinical trials and will retain the rights to co-develop, co-commercialize and share in profits. Celgene has an exclusive option to license demcizumab, OncoMed's most advanced product which is in early-stage trials. OncoMed will be eligible to receive 50% of U.S. profits and royalties for sales internationally if demcizumab makes it to market.

As part of the agreement, OncoMed will receive $177.25 million in an upfront payment from Celgene. Celgene will also purchase $22.25 million of OncoMed's shares, giving it an approximate 5% stake in the company.

"By retaining co-development and co-commercialization rights to up to five biologic product candidates in our pipeline, we expect to add commercial capabilities to our core research and development competencies as we continue to build a premier oncology biotherapeutics company," said OncoMed CEO Paul J. Hastings.

Celgene shares fell 0.95% at market open. The Summit, N.J.-based company is up 107.9% since January.

--Written by Keris Alison Lahiff.

Also see: The 10 Drunkest States in America... and the 10 most sober.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%